ArticlePediatric research2026
Serum uric acid/creatinine ratio and metabolic-associated fatty liver disease risks in children.
Article in Pediatric research, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
3 citing papers in PubMed.
- Redox-Metabolic Crosstalk in Pediatric MASLD: Biomarkers, Mechanisms, and the Emerging Role of Selenium.International journal of molecular sciences · 2026Review
- Determinants of Liver Steatosis Progression in Chinese Children: A Prospective Cohort Study.Diabetes, metabolic syndrome and obesity : targets and therapy · 2026Article
- The association of serum uric acid level and the uric acid to creatinine ratio with non alcoholic fatty liver disease in children with obesity.Scientific reports · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
objectivesTo investigate the correlation between serum uric acid/creatinine ratio (SUA/Cr) and Metabolic-associated fatty liver disease (MAFLD) in children.
methods1387 participants aged 4-15 who underwent health examinations from 1/2020-12/2023 were included. Clinical indicators were compared and analyzed.
resultsOverweight/obese group had elevated levels compared to non-overweight/obese group in male proportion, uric acid (UA), serum uric acid/creatinine ratio (SUA/Cr), systolic blood pressure (SBP), diastolic blood pressure (DBP), alanine aminotransferase (ALT), gamma-glutamyltransferase(GGT), total protein(TP), albumin(ALB), globulin(GLO), and serum creatinine(SCr) (p < 0.001, Kruskal-Wallis test). As SUA/Cr increased, UA, ALT, ALP, TP, GGT levels and the prevalence rates of overweight/obesity rose, while SCr levels fell (p < 0.05, Jonckheere-Terpstra test), and positively related to body mass index (BMI) (p < 0.05). The OR for overweight/obesity increased in higher SUA/Cr quartile groups, as Q3 (OR = 2.399, 95% confidence interval CI = 1.554-3.703) and Q4 (OR = 5.044, 95% CI = 3.281-7.754). The SUA/Cr exhibited an AUC of 0.828 (95% CI = 0.764-0.892, p < 0.001) in predicting overweight/obesity and elevated ALT levels, with a specificity of 0.764 and sensitivity of 0. 805.
conclusionsChildren with overweight/obesity have higher liver enzymes, and elevated SUA/Cr levels may predict an increased incidence of overweight/obesity and hepatic injury. IMPACT: This study found a close association between serum uric acid/creatinine ratio (SUA/Cr) and risk factors for Metabolic-associated fatty liver disease (MAFLD) in children. SUA/Cr may be an indicator of risk factors for MAFLD in children. Elevated SUA/Cr levels may predict an increased incidence of overweight/obesity and hepatic injury. Providing an easily accessible non-invasive biomarker for predicting and preventing MAFLD in children.
Indexed as
Identifiers
40537539What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.